Neko Health, a Stockholm-based health technology company co-founded by Spotify CEO Daniel Ek, has raised €612.7M ($700M) in a Series C round led by Lightspeed Venture Partners and co-led by O.G.
Venture Partners, with participation from existing and new investors. The round follows a €250M Series B closed in January 2025. The company will use the funding to open its first clinics in the United States, starting with New York later this year, while continuing to invest in the research and technology underpinning its preventive health model.
Addressing The Market Opportunity
Healthcare systems around the world are built primarily around treating illness after it has already developed. Preventive care, the practice of detecting and addressing health problems before they become serious, remains underdeveloped relative to its potential impact on outcomes and costs. Neko Health was founded on the premise that a fundamentally different healthcare experience is possible, one designed to keep people healthy rather than respond to disease after the fact.
Advertisement
How The Technology Works
Neko Health combines proprietary scanning technology, clinical research, and in-person health assessments by doctors into a single end-to-end healthcare experience. The company’s model is built around early detection, using advanced imaging and health data to identify problems at a stage when intervention is most effective.
The company tracks member health over time, with return visits used to monitor whether health markers are moving in the right direction. Neko Health reports that the vast majority of members return after their first scan, and that repeat members show measurable improvement in key health indicators.
Growth And Market Traction
Founded in 2023 by Hjalmar Nilsonne and Daniel Ek, Neko Health has grown rapidly since opening its first clinic three years ago. The Series C follows a Series B of €250M closed eighteen months earlier, reflecting sustained investor conviction in both the model and its commercial momentum. David Ofer from O.G. Venture Partners will join the Board of Directors following the investment.
Expansion Plans
The $700M raise will fund Neko Health’s entry into the United States, with New York as the first location and additional cities to follow later in 2026. The company will continue building out its research and technology capabilities in parallel with its geographic expansion.
Looking Ahead
Hjalmar Nilsonne, co-founder and CEO of Neko Health, described the continuity between the company’s founding mission and its next phase of growth: “This funding is a strong vote of confidence in what we set out to do when we opened our first clinic three years ago: a completely new healthcare experience designed to keep people healthy, catch problems early and help prevent disease before it even starts. With this round, we’re taking that mission to the US for the first time, while continuing to invest in the research and technology that make prevention possible at scale.”
Bejul Somaia, Global Partner at Lightspeed Venture Partners, outlined the firm’s conviction in the company: “Over the past eighteen months, Neko Health has demonstrated remarkable innovation and growth, attacking one of the largest markets in the world with breakthrough technology, proven consumer demand, and a clear path to global scale. We believe this is one of the most important healthcare companies of our generation, and we’re proud to deepen our partnership as they continue to reimagine prevention.”
About Neko Health
Neko Health is a Stockholm-based health technology company founded in 2023 by Hjalmar Nilsonne and Daniel Ek. The company operates preventive health clinics that combine proprietary scanning technology, clinical research, and doctor-led health assessments to detect health problems early and help members improve their health over time. Following its $700M Series C, the company is expanding into the United States with its first clinics opening in New York in 2026.
